Michael M Richter, Ida M Kemp, Sara Heebøll, Marie Winther-Sørensen, Sasha A S Kjeldsen, Nicole J Jensen, Janus D Nybing, Frederik H Linden, Erik Høgh-Schmidt, Mikael P Boesen, Sten Madsbad, Frank Vinholt Schiødt, Kirsten Nørgaard, Signe Schmidt, Lise Lotte Gluud, Steen B Haugaard, Jens J Holst, Søren Nielsen, Jørgen Rungby, Nicolai J Wewer Albrechtsen
INTRODUCTION: Glucagon receptor agonism is currently explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The metabolic effects of glucagon receptor agonism may in part be mediated by increases in circulating levels of Fibroblast Growth Factor 21 (FGF21) and Growth Differentiation Factor 15 (GDF15). The effect of glucagon agonism on FGF21 and GDF15 levels remains uncertain, especially in the context of elevated insulin levels commonly observed in metabolic diseases...
April 15, 2024: Metabolism: Clinical and Experimental